BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 17519947)

  • 1. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.
    Lebrecht D; Setzer B; Ketelsen UP; Haberstroh J; Walker UA
    Circulation; 2003 Nov; 108(19):2423-9. PubMed ID: 14568902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Kratz F; Walker UA
    Int J Cancer; 2007 Feb; 120(4):927-34. PubMed ID: 17131338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin.
    Lebrecht D; Kokkori A; Ketelsen UP; Setzer B; Walker UA
    J Pathol; 2005 Dec; 207(4):436-44. PubMed ID: 16278810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
    Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
    Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy.
    Lebrecht D; Kirschner J; Geist A; Haberstroh J; Walker UA
    Cardiovasc Pathol; 2010; 19(5):e167-74. PubMed ID: 19747854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
    Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
    Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and prevention of doxorubicin cardiomyopathy.
    Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
    Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
    Silber JH
    Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.